How much does each box of Ocriplasmin cost?

Ocriplasmin (Ocriplasmin) is an ophthalmic prescription drug with an innovative mechanism. It was developed by the Belgian pharmaceutical company ThromboGenics. It was approved by the US FDA in October 2012 for the treatment of symptomatic vitreomacular adhesion (VMT). Its unique principle of action is to help the vitreous in the macular area naturally separate by cleaving fibronectin in the vitreous, thereby reducing traction pressure and avoiding further retinal holes or macular damage. The emergence of this drug provides a new option for non-surgical treatment for patients with early-stage VMT.

Currently, Oak Plasmin has not been officially launched in China, so there is no official domestic selling price, and it has not been included in the scope of medical insurance reimbursement. According to overseas drug databases and U.S. market public information, Ocriplasmin is sold in single-dose packaging of 2.5 mg/ml, and its specifications are suitable for single intravitreal injection. Its market price in the United States and Europe is approximately US$4,000 per box (equivalent to approximately RMB 28,000), and the price may fluctuate slightly in different countries and regions due to import taxes and hospital differences.

SinceOcriplasmin does not yet have a generic version, and currently only the original version is available in the global market, which is also one of the important reasons why the price remains high. Its research and development costs, cold chain storage and transportation, and special ophthalmic injection operation requirements all have an impact on the price. Although expensive, this drug still has certain clinical value for some patients who want to avoid vitrectomy and preserve macular function.

It is worth noting that Oak Plasmin is usually only used in specialized eye hospitals or institutions with intravitreal injection qualifications, and each drug needs to be injected within a short time after preparation to ensure the stability of the active protein. At present, some regions in Asia (such as Japan, etc.) have successively approved the listing, and the price is generally maintained at a level similar to the European and American markets.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html